Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shigella4V2 safety and immunogenicity study in 9-month-old Kenyan infants
PACTR202408653853505Phase 2Completed
- Sponsor
- LimmaTech Biologics
- Start
- Feb 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of Shigella4V in shigellosis (3 arms), sponsored by LimmaTech Biologics. Started Feb 2025; status: completed.
02
Drugs
Shigella4V
03
Conditions
shigellosis
Beyond the preview
Go deeper on PACTR202408653853505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202408653853505.